相关临床试验
7
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
2
28.6%
已完成
2
28.6%
招募中
3
42.9%
暂无批准数据
- The global fill-finish manufacturing market reached roughly US$11 billion in 2025, with more than US$27 billion committed to expanding sterile capacity across 2024–2025 alone. - The GLP-1 boom has displaced non-GLP-1 sterile products from existing filling lines, forcing sponsors of antibodies, vaccines, and specialty injectables to seek new manufacturing partners. - Asia-Pacific is building isolator-first, device-aware fill-finish capacity faster than any other region, though equipment qualification lead times of 12–18 months mean most expansions will not be operational until 2027–2028. - The revised EU GMP Annex 1 has raised the regulatory floor globally, making the Contamination Control Strategy a mandatory, inspection-ready system that directly constrains throughput and batch risk.
- Biocon Academy celebrated its 10th Graduation Ceremony in Bengaluru, graduating 156 students across five specialized biosciences programs. - Women represented 70% of the graduating cohort, and seven top-performing students received Gold Medals for Academic Excellence. - The Academy has trained over 1,300 students since 2013 through industry-aligned programs bridging the gap between academia and the biopharmaceutical sector. - New programs in Artificial Intelligence in Life Sciences and Drug Metabolism and Pharmacokinetics were announced to align curriculum with emerging industry needs.
- President Trump announced 100% tariffs on all imported branded and patent-protected medicines to the US starting October 1, 2025, unless companies are actively building manufacturing plants in America. - Indian pharmaceutical stocks plummeted up to 5% following the announcement, with Sun Pharma hitting its yearly low and the Nifty Pharma Index declining 2.54%. - The policy could significantly impact Indian pharma companies that generate substantial revenue from US exports, potentially affecting over $233 billion of US pharma imports while exempting generic drug exporters. - Companies may face reduced profits or be forced to invest in expensive US manufacturing facilities to avoid the tariffs and maintain market access.
- Indian Contract Research and Development and Manufacturing Organizations (CRDMOs) are attracting increased attention from global pharmaceutical companies as Big Pharma pursues geographic diversification strategies. - Rising demand for antibody-drug conjugate (ADC)-related CDMO services and future opportunities in GLP-1 diabetes and obesity treatments are positioned as significant growth drivers from 2026. - Key players including Piramal Pharma, Syngene, Laurus Labs, Cohance, and Gland Pharma are strategically positioning for future gains despite current destocking challenges affecting near-term growth. - Gland Pharma is expanding its GLP-1 cartridge fill-finish capacity from 40 million to 140 million units by the end of next year, reflecting the industry's optimistic long-term outlook.
• Biocon plans to invest $150 million in capital expenditure over the next two years, with $100 million allocated to biologics expansion in Malaysia and $50 million to generics. • The biopharmaceutical company reported a 153% surge in Q4 net profit to Rs 344 crore, driven by strong growth in generics and steady progress in biosimilars. • Biocon is expanding its product portfolio with recent launches of lenalidomide and dasatinib in the US, liraglutide in the UK, and plans to launch bevacizumab and insulin aspart in the US market.
• Genflow Biosciences has received a £434,083 institutional investment to accelerate its 2025 programs, including a clinical trial testing SIRT6 gene therapy in aged dogs. • The company has commenced a randomized, controlled trial with 28 dogs aged 10+ years to evaluate the safety and efficacy of its proprietary SIRT6-centenarian gene therapy for age-related decline. • CEO Dr. Eric Leire has separately invested £500,000 in the company, calling it "a strong vote of confidence in our science" as Genflow advances research that could potentially benefit both veterinary and human medicine.
• Antibody-drug conjugates (ADCs) are gaining traction in APAC, marked by significant investments and collaborations, particularly from Chinese companies, signaling strong potential in targeted cancer therapies. • Cell and gene therapies (CGTs) are experiencing a surge in APAC, with China leading in CAR-T clinical trials and approvals, indicating a growing focus on innovative treatments for oncology and other diseases. • Artificial intelligence (AI) is becoming integral in APAC's pharmaceutical sector, enhancing drug discovery, clinical trials, and personalized medicine, with AI-designed drugs nearing regulatory approval. • The APAC region is solidifying its dominance in clinical trials, driven by a large patient population and regulatory reforms, particularly in oncology, attracting both local and global pharmaceutical firms.
